Health Care [ 10/12 ] | Biotechnology [ 54/74 ]
NASDAQ | Common Stock
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.
Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital.
The company was founded in 2015 and is based in Wilmington, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 24 | -0.67 Decreased by -458.33% | -0.69 Increased by +2.90% |
| May 14, 24 | -0.74 Decreased by -362.50% | -0.55 Decreased by -34.55% |
| Mar 29, 24 | -0.50 Decreased by -212.50% | -0.70 Increased by +28.57% |
| Nov 13, 23 | -0.07 Increased by +50.00% | -0.11 Increased by +36.36% |
| Aug 14, 23 | -0.12 Decreased by -9.09% | -0.14 Increased by +14.29% |
| May 15, 23 | -0.16 Increased by +23.81% | -0.14 Decreased by -14.29% |
| Mar 31, 23 | -0.16 Increased by +69.81% | -0.14 Decreased by -14.29% |
| Nov 14, 22 | -0.14 Increased by +65.00% | -0.14 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.90 M Increased by +9.41% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 8.00 K Increased by +N/A% | -6.53 M Increased by +48.37% | Decreased by -81.60 K% Decreased by N/A% |
| Dec 31, 23 | 8.00 K Increased by +N/A% | -4.33 M Increased by +24.28% | Decreased by -54.15 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -6.06 M Increased by +32.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.72 M Decreased by -99.75% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.64 M Decreased by -12.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -5.72 M Increased by +81.42% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -9.03 M Increased by +56.55% | Decreased by N/A% Decreased by N/A% |